The purpose of this study is to determine the effect of statin therapy for prevention of atrial fibrillation (AF) in pacemaker and non-pacemaker patients with paroxysmal atrial fibrillation in the absence of significant coronary artery disease.

Patients with a history of paroxysmal atrial fibrillation, with or without a dual chamber pacemaker and who meet all study criteria, will be randomized to receive either a placebo, or simvastatin 40 mg, daily for 6 months.

Liver enzymes are drawn at randomization and 3 months. CRP and oxidative stress products are drawn at randomization, weekly for the first month and then monthly for 5 months.

Patients transmit their rhythm, twice daily for 5 consecutive days at randomization, then 5 consecutive days monthly for 6 months.

Clinic visits are required at randomization, 3 months and 6 months.

Inclusion Criteria:

• Patients with paroxysmal AF (> 3 epis each > 15 min in length) over 6 months
• Patients on stable antiarrhythmic drug therapy and life expectancy > 1 year

Exclusion Criteria:

• Patients with PAF due to reversible cause
• Chronic inflammatory conditions
• Other medical conditions requiring statin therapy
• Patients on amiodarone or verapamil
• Elevated CK or ALT
• Life expectancy <1 year
• TAVN ablation
• Geographic isolation
• Inability to give informed consent